Core Insights - Catheter Precision, Inc. has received a notice of allowance for its first US patent for the LockeT product, a surgical closure device for orthoscopic entry wounds, filed in December 2022 [1][2] - The company has also secured international patents for LockeT in China, Europe, and the United Kingdom, which is significant for its distribution discussions in these markets [2] - The company anticipates receiving the CE mark for LockeT within the current quarter, enabling revenue generation in Europe [2] Company Overview - Catheter Precision is a US-based medical device company focused on innovative solutions for cardiac arrhythmias, emphasizing the development of advanced technology for electrophysiology procedures [4] - The LockeT device is a Class 1 suture retention device designed to assist in wound closure after percutaneous venous punctures and is registered with the FDA [3] Market Position - The company has begun rolling out LockeT in the US market and has received positive feedback from hospitals, indicating a demand for products that improve outcomes while reducing costs per procedure [2]
Catheter Precision, Inc. Receives Notice of First Patent Allowance in the US for LockeT Product Line